Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Adial Pharmaceuticals, Inc - Common Stock (NQ:ADIL)

2.955 -0.075 (-2.48%)
Streaming Delayed Price Updated: 12:56 PM EST, Feb 11, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Adial Pharmaceuticals, Inc - Common Stock

< Previous 1 2 3 4 5 6 7 8 Next >
News headline image
12 Health Care Stocks Moving In Thursday's After-Market Session ↗
 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Thursday's Pre-Market Session ↗
 
Via Benzinga
News headline image
EXCLUSIVE: Adial Pharmaceuticals Expands Patent Portfolio With New US Patent For Lead Drug For Alcohol And Opioid Use Disorders ↗
Adial secures USPTO patent for AD04, expanding coverage to treat alcohol and opioid-related disorders in patients with genetic markers. 
Via Benzinga
Topics Intellectual Property
News headline image
12 Health Care Stocks Moving In Monday's After-Market Session ↗
 
Via Benzinga
News headline image
EXCLUSIVE: After FDA Response, Adial Starts Manufacturing Clinical Supplies For Upcoming Phase 3 Program Of Lead Candidate For Alcohol Use Disorder ↗
Adial Pharmaceuticals secured FDA support for its AD04 bridging strategy, paving the way for Phase 3 trials in 2025 after confirming bioequivalence. 
Via Benzinga
News headline image
EXCLUSIVE: Adial Pharmaceuticals Secures New US Patent Covering Genotype-Specific Treatment of Opioid-Related Disorders ↗
Adial Pharmaceuticals received a U.S. patent for genetic marker-based treatment methods and completed a pharmacokinetics study supporting its Phase 3 trial. 
Via Benzinga
Topics Intellectual Property
News headline image
EXCLUSIVE: Adial Pharmaceuticals Reveals Positive Pharmacokinetics Study Results Of AD04 For Alcohol Use Disorder ↗
Adial Pharmaceuticals announced completion of PK study for AD04, confirming predictable bioavailability, dose proportionality, and no food effect. 
Via Benzinga
News headline image
EXCLUSIVE: Adial Pharmaceuticals' Lead Drug Secures Key US Patent For Alcohol Dependence Based on Expanded Genotype Combinations ↗
Adial Pharmaceuticals expands its IP with a U.S. patent for targeted AUD treatment using AD04, supporting its personalized medicine strategy. 
Via Benzinga
Topics Intellectual Property
News headline image
12 Health Care Stocks Moving In Thursday's Pre-Market Session ↗
 
Via Benzinga
News headline image
EXCLUSIVE: Adial Pharmaceuticals Reveals Topline Results From Pharmacokinetics Study Of AD04 For Alcohol Use Disorder ↗
Adial Pharmaceuticals completes PK study for AD04 in AUD, meeting FDA requirements and preparing for Phase 3 trial. Data supports 505(b)(2) application. 
Via Benzinga
News headline image
This Turning Point Brands Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Thursday ↗
 
Via Benzinga
News headline image
EXCLUSIVE: Adial Pharmaceuticals Secures Additional US Patent Expanding Intellectual Property Protection Around Its Alcohol Use Disorder Candidate ↗
Adial Pharmaceuticals secures a new patent allowance for AD04, enhancing its precision medicine approach for treating alcohol use disorder. Topline results from AD04's latest study are expected in Q4... 
Via Benzinga
Topics Intellectual Property
News headline image
ADIL Stock Earnings: Adial Pharmaceuticals Reported Results for Q2 2024 ↗
Adial Pharmaceuticals just reported results for the second quarter of 2024. 
Via InvestorPlace
News headline image
EXCLUSIVE: Adial Pharmaceuticals Advances Regulatory Strategy For Companion Diagnostic Genetic Test For Its Lead Program For Alcohol Use Disorder ↗
Adial Pharmaceuticals has partnered with Boudicca Dx to advance the regulatory and technical strategy for its companion diagnostic test for AD0 for Alcohol Use Disorder. This collaboration is pivotal... 
Via Benzinga
News headline image
EXCLUSIVE: Adial Pharmaceuticals' Last Patient Dosed in Pharmacokinetics Study of AD04 For Alcohol Use Disorder, Data Expected In Q4 ↗
Adial Pharmaceuticals announces the completion of the pharmacokinetics study dosing for AD04, their lead investigational treatment for Alcohol Use Disorder in heavy drinking patients. Topline results... 
Via Benzinga
News headline image
Gold Moves Higher; Coca-Cola Increases FY24 Forecast ↗
 
Via Benzinga
News headline image
Why Comcast Shares Are Trading Lower By 6%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session ↗
 
Via Benzinga
News headline image
Why Is Serve Robotics (SERV) Stock Down Today? ↗
Serve Robotics stock is down on Tuesday after the company revealed the pricing of warrants for SERV shares in a private placement. 
Via InvestorPlace
News headline image
Why Is Jaguar Health (JAGX) Stock Down 55% Today? ↗
Jaguar Health stock is down on Tuesday as JAGX investors react to failed results from a Phase 3 clinical trial of crofelemer. 
Via InvestorPlace
News headline image
Crude Oil Down 2%; GE Aerospace Earnings Top Views ↗
 
Via Benzinga
News headline image
Why Is Adial Pharmaceuticals (ADIL) Up 61% Today? ↗
Adial Pharmaceuticals stock is up with heavy trading of ADIL after providing investors with an update on its AD04 clinical trial. 
Via InvestorPlace
News headline image
US Stocks Edge Higher; General Motors Posts Upbeat Earnings ↗
 
Via Benzinga
News headline image
EXCLUSIVE: Adial Pharmaceuticals Moves Forward To Second Cohort In Pharmacokinetics Study of AD04 For Alcohol Use Disorder ↗
Adial Pharmaceuticals progresses to the second cohort in the AD04 pharmacokinetics study for Alcohol Use Disorder. This study, involving up to 30 healthy volunteers, will provide critical insights for... 
Via Benzinga
News headline image
ADIL Stock Earnings: Adial Pharmaceuticals Beats EPS for Q4 2023 ↗
ADIL stock results show that Adial Pharmaceuticals beat analyst estimates for earnings per share the fourth quarter of 2023. 
Via InvestorPlace
News headline image
EXCLUSIVE: Adial Pharmaceuticals Announces Publication In Journal Supporting the Potential Efficacy Of AD04 For Alcohol Use Disorder ↗
Adial Pharmaceuticals publishes Phase 3 ONWARD study results in the European Journal of Internal Medicine. The study reveals AD04 significantly reduces heavy drinking days, with adverse events matching... 
Via Benzinga
News headline image
MicroCap Rodeo’s Spring into Summer Conference, June 6th 2024 - 25 Presenting Companies
Via ACCESSWIRE
News headline image
Millionaire Makers: 7 Stocks You Can Buy for $2 That Can 10X by 2025 ↗
These 10X penny stocks have the potential to mint millionaires with enough capital but buy wisely as the risk is real. 
Via InvestorPlace
News headline image
EXCLUSIVE: Adial Pharmaceuticals Starts Patient Dosing In Pharmacokinetics Study Of AD04 For Alcohol Use Disorder ↗
Adial Pharmaceuticals starts dosing in pharmacokinetics study of AD04 for Alcohol Use Disorder in heavy drinking patients. Topline results in early Q4 2024. 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Friday's After-Market Session ↗
 
Via Benzinga
News headline image
ADIL Stock Earnings: Adial Pharmaceuticals Misses EPS for Q1 2024 ↗
ADIL stock results show that Adial Pharmaceuticals missed analyst estimates for earnings per share the first quarter of 2024. 
Via InvestorPlace
< Previous 1 2 3 4 5 6 7 8 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.